Augmentation of Muscle Blood Flow by Ultrasound Cavitation Is Mediated by ATP and Purinergic Signaling

Abstract

Background Augmentation of tissue blood flow by therapeutic ultrasound is thought to rely on convective shear. Microbubble contrast agents that undergo ultrasound-mediated cavitation markedly amplify these effects. We hypothesized that purinergic signalling is responsible for shear-dependent increases in muscle perfusion during therapeutic cavitation. Methods Unilateral exposure of the proximal hindlimb of mice (with or without ischemia produced by iliac ligation) to therapeutic ultrasound (1.3 MHz, mechanical index 1.3) was performed for ten minutes after intravenous injection of 2×108 lipid microbubbles. Microvascular perfusion was evaluated by low-power contrast ultrasound perfusion imaging. In vivo muscle ATP release and in vitro ATP release from endothelial cells or erythrocytes were assessed by a luciferin-luciferase assay. Purinergic signalling pathways were assessed by studying interventions that either (1) accelerated ATP degradation; (2) inhibited P2Y receptors, adenosine receptors, or KATP channels; or (3) inhibited downstream signalling pathways involving endothelial nitric oxide synthase (eNOS) or prostanoid production (indomethacin). Augmentation in muscle perfusion by ultrasound cavitation was assessed in a proof-of-concept clinical trial in 12 subjects with stable sickle cell disease (SCD). Results Therapeutic ultrasound cavitation increased muscle perfusion by 7-fold in normal mice, reversed tissue ischemia for up to 24 hrs in the murine model of peripheral artery disease, and doubled muscle perfusion in patients with SCD. Augmentation in flow extended well beyond the region of ultrasound exposure. Ultrasound cavitation produced a nearly 40-fold focal and sustained increase in ATP, the source of which included both endothelial cells and erythrocytes. Inhibitory studies indicated that ATP was a critical mediator of flow augmentation that acts primarily through either P2Y receptors or through adenosine produced by ectonucleotidase activity. Combined indomethacin and inhibition of eNOS abolished the effects of therapeutic ultrasound, indicating downstream signalling through both NO and prostaglandins. Conclusions Therapeutic ultrasound using microbubble cavitation to increase muscle perfusion relies on shear-dependent increases in ATP which can act through a diverse portfolio of purinergic signalling pathways. These events can reverse hindlimb ischemia in mice for >24 hours, and increase muscle blood flow in patients with sickle cell disease. Clinical Trial Registration NCT01566890 (https://clinicaltrials.gov/ct2/show/NCT01566890)

The Role of Ultrasound-Driven Microbubble Dynamics in Drug Delivery: From Microbubble Fundamentals to Clinical Translation

“…This has led to a growth delay in tumors, caused by the endothelial cell apoptosis and local inflammation resulting in platelet activation and occlusion of the microvasculature [149][150][151] . In contrast, an increased perfusion after microbubble-assisted ultrasound treatment was also described in literature [152][153][154] . Rix et al 153 reported augmented signal enhancement in tumors after repeated microbubble injections and mentioned cavitation-assisted mechanical opening of closed microvessels as one of the possible reasons.…”

The Role of Nitric Oxide during Sonoreperfusion of Microvascular Obstruction

“…This group also described an increase in flow rate in a model of chronic ischemia three days after MB+US therapy. Recently, it was shown that MB and ultrasound induced increase in blood flow was mediated by adenosine triphosphate (ATP) and purinergic signaling 33 , which can stimulate the eNOS and/or adenosine and prostanoid pathways. Consistent with our findings, this study also found that LNAME blunted the blood flow increase observed after MB+US treatment.…”

Ultrasound-Induced Microbubble Cavitation for the Treatment of Catheterization-Induced Vasospasm

“…We do not believe it was related to any effect of the previous interventions performed at least 7 days earlier, since the Definity MB half-life is in minutes. However, a prolonged NO effect from the previous treatment cannot totally be ruled out based on the statistical analysis (31) .…”